17412-23-6

Basic information

• Product Name: 6-chloro-2,8-dimethyl-Imidazo[1,2-b]pyridazine
• Synonyms: 6-chloro-2,8-dimethyl-Imidazo[1,2-b]pyridazine
• CAS NO: 17412-23-6
• Molecular Formula: C₈H₈ClN₃
• Molecular Weight: 181.62222
• Product Categories: Risdiplam
• Mol File: 17412-23-6.mol
• Article Data: 8

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 6-chloro-2,8-dimethyl-Imidazo[1,2-b]pyridazine(CAS DataBase Reference)
• NIST Chemistry Reference: 6-chloro-2,8-dimethyl-Imidazo[1,2-b]pyridazine(17412-23-6)
• EPA Substance Registry System: 6-chloro-2,8-dimethyl-Imidazo[1,2-b]pyridazine(17412-23-6)

Safety Data

• Hazardous Substances Data: 17412-23-6(Hazardous Substances Data)

Usage

General Description

6-Chloro-2,8-dimethyl-Imidazo[1,2-b]pyridazine is a chemical compound with a molecular formula of C8H7ClN4. As indicated by its name, this substance has both a chlorine and two methyl groups attached to an imidazo[1,2-b]pyridazine ring. This kind of structure is commonly seen in a range of organic compounds, particularly in heterocyclic compounds. The properties and uses of the specific chemical 6-Chloro-2,8-dimethyl-Imidazo[1,2-b]pyridazine largely depend on its exact structural conformation and the context in which it is used, making it a potential candidate for research in various scientific fields, including medicinal chemistry or organic synthesis. However, detailed information about this particular chemical is not widely available in the public domain, indicating that it might not yet have been extensively studied.

Upstream product

• 64068-00-4 3-amino-6-chloro-4-methylpyridazine 
• 78-95-5 chloroacetone 
• 19064-64-3 3,6-dichloro-4-methylpyridazine 
• 126-38-5 1-bromo-2,2-dimethoxypropane 
• 598-31-2 1-bromoacetone 

Downstream Products

• 1825352-86-0 2,8-dimethyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)imidazo[1,2-b]pyridazine 
• 1825352-65-5 7-(4,7-diazaspiro[2.5]octan-7-yl)-2-(2,8-dimethylimidazo[l,2- b]pyridazin-6-yl)-4H-pyrido[l,2-a]pyrimidin-4-one 

Relevant articles and documents

COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY

The present invention provides compounds of formula (I) wherein A, R1, R2 and R3 are as described herein, as well as pharmaceutically acceptable salts thereof. Further the present invention is concerned with the manufacture of the compounds of formula (I), pharmaceutical compositions comprising them and their use as medicaments.

Discovery of Risdiplam, a Selective Survival of Motor Neuron-2 (SMN2) Gene Splicing Modifier for the Treatment of Spinal Muscular Atrophy (SMA)

SMA is an inherited disease that leads to loss of motor function and ambulation and a reduced life expectancy. We have been working to develop orally administrated, systemically distributed small molecules to increase levels of functional SMN protein. Compound 2 was the first SMN2 splicing modifier tested in clinical trials in healthy volunteers and SMA patients. It was safe and well tolerated and increased SMN protein levels up to 2-fold in patients. Nevertheless, its development was stopped as a precautionary measure because retinal toxicity was observed in cynomolgus monkeys after chronic daily oral dosing (39 weeks) at exposures in excess of those investigated in patients. Herein, we describe the discovery of 1 (risdiplam, RG7916, RO7034067) that focused on thorough pharmacology, DMPK and safety characterization and optimization. This compound is undergoing pivotal clinical trials and is a promising medicine for the treatment of patients in all ages and stages with SMA.

COMPOSITIONS FOR TREATING SPINAL MUSCULAR ATROPHY

The present invention provides pharmaceutical compositions comprising a compound of formula (I) wherein A, R1, R2 and R3 are as described herein, as well as pharmaceutically acceptable salts thereof. Further the present invention is concerned with the manufacture of the pharmaceutical compositions comprising a compound of formula (I) and their use as medicaments.